Kinase Profiling Inhibitor Database

This is a searchable database of specificities of 254 commonly used signal transduction inhibitors. These results have been provided by the International Centre for Kinase profiling within the MRC Protein Phosphorylation Unit at the University of Dundee.

We strongly recommend undertaking kinase profiling of any kinase inhibitor to be used in a biological experiment. It is essential to have a good feel for the specificity of the kinase inhibitor you are working with in order to be able to properly interpret your data.

If you have additional kinase inhibitors that you would like the International Centre for Kinase profiling team to profile for you please contact us here for further details.

If you have any feedback or suggestions on how to improve this resource we welcome your input. Pass on your ideas to us here.

Compound name Brutto MW Action Reference Reference 2
(5Z)-7-Oxozeaenol   C19H22O7 362.37 TAK1 Ninomiya-Tsuji (2003) J.Biol.Chem. 278 18485 Windheim et al (2007) Biochem.J. 404 179
1 NA-PP1 (PP1 Analog)   C19H19N5 317.40 Src Bishop A. C. (2000) Nature 407 395 https://pubmed.ncbi.nlm.nih.gov/[pmid2]
1 NM-PP1 (PP1 Analog II)   C20H21N5 331.40 Src Ira G. (2004) Nature 431 1011 Papa F.R. (2003) Science 302 1533
2-Aminopurine   C5H5N5 135.13 PKR https://pubmed.ncbi.nlm.nih.gov/[pmid1] https://pubmed.ncbi.nlm.nih.gov/[pmid2]
A-443654   C24H23ON5x2HCl 470.39 Akt1 Shi Y. (2005) Neoplasia 7 992-1000. https://pubmed.ncbi.nlm.nih.gov/[pmid2]
A-769662   C20H12N2O3S 360.39 AMPK Activator Cool B. (2006) Cell Metabolism 3 403-416 https://pubmed.ncbi.nlm.nih.gov/[pmid2]
A-83-01   C25H19N5S 421.52 ALK5 Tojo (2005) Cancer.Sci. 96 791 https://pubmed.ncbi.nlm.nih.gov/[pmid2]
ADP-D-b-D-Hep   C17H33N7O16P2 653.43 activator ALPK1 https://pubmed.ncbi.nlm.nih.gov/[pmid1] https://pubmed.ncbi.nlm.nih.gov/[pmid2]
ADP-L-b-D-Hep   C17H33N7O16P2 653.43 activator ALPK1 https://pubmed.ncbi.nlm.nih.gov/[pmid1] https://pubmed.ncbi.nlm.nih.gov/[pmid2]
AG1296 (Tyrphostin)   C16H14N2O2 266.29 PDGF Kovalenko M. (1994) Cancer Res. 54 6106 https://pubmed.ncbi.nlm.nih.gov/[pmid2]
AG1478 (Tyrphostin)   C16H14ClN3O2 315.75 EGFR Osherov N. (1994) A. Eur. J. Biochem. 225 1047 https://pubmed.ncbi.nlm.nih.gov/[pmid2]
AG490   C17H14N2O3 294.30 EGFR, JAK Jaleel M. (2004) Biochemistry 43 8247 Eriksen K.W. (2001) Leukemia 15 787
AG879 (Tyrphostin)   C18H24N2OS 316.50 Tyrosine-kinases Konrad R.J. (1996) J. Biol. Chem. 271 24179 Levitzki A. Gazit A. (1995) Science 267 1782
Akt Inhibitor IV   C31H27IN4S 614.60 Akt Kau T. R. (2003) Cancer Cell 4 463 https://pubmed.ncbi.nlm.nih.gov/[pmid2]
Akti 1/2   C34H29N7O 551.60 Akt1, Akt2 Logie L. (2007) Diabetes 2218-27 Barnett S.F. (2005) Biochem. J. 385 399
Alsterpaullone   C16H11N3O3 293.30 GSK3b, CDK5/p25, CDK1/cyclin B Leost M. (2000) Eur. J. Biochem. 267 5983 Schultz C. (1999) J. Med. Chem. 42 2909
Amgen TBK 1 inhibitor (Compound II)   C28H35N7O4 533.62 TBK1 Ou Y.H. (2011) Molecular Cell 41 458-470 https://pubmed.ncbi.nlm.nih.gov/[pmid2]
Amgen-NIK-28   C20H20N4O 332.40 NIK https://pubmed.ncbi.nlm.nih.gov/[pmid1] https://pubmed.ncbi.nlm.nih.gov/[pmid2]
Amlexanox   C16H14N2O4 298.29 TBK1, IKKe https://pubmed.ncbi.nlm.nih.gov/[pmid1] https://pubmed.ncbi.nlm.nih.gov/[pmid2]
ARA014418   C12H12N4O4S 308.30 GSK3 Noble W. (2005) Proc. Natl. Acad. Sci. USA 102 6990 Bhat R. (2003) J. Biol. Chem. 278 45937